Sort   by:  
 Page size 
UnknownPharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Not available
S-EPMC4546409 | biostudies-literature
UnknownImpact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
Not available
S-EPMC7932918 | biostudies-literature
UnknownEfficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Not available
S-EPMC4832070 | biostudies-literature
ProteomicsLenalidomide induces ubiquitination and degradation of casein kinase 1A1 in del(5q) MDS
Not available
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2015-01-26 | MSV000079014 | MassIVE
UnknownMCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Not available
S-EPMC7280535 | biostudies-literature
UnknownLeukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Not available
S-EPMC8110775 | biostudies-literature
UnknownRestenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial.
Not available
S-EPMC3912998 | biostudies-literature
UnknownNeuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
Not available
S-EPMC7313925 | biostudies-literature
Sort   by:  
 Page size